Heart failure & cardiomyopathies
Effects of Angiotensin Receptor-Neprilysin Inhibitor on Insulin Resistance in Patients with Heart Failure
Authors' conclusion
In conclusion, even in a short period of only 3 months, the administration of ARNI improved insulin resistance and consequently reduced the serum uric acid levels in patients with stable chronic heart failure.
Study context
- Population
- Outpatients with stable chronic HF taking ACEi or angiotensin receptor blockers (ARBs), October 2021–July 2022
- Participants
- 34 outpatients
- Exposure
- Angiotensin receptor-neprilysin inhibitor (ARNI) vs continued ACEi or ARB
- ARNIn = 17
- Controln = 17reference
- Outcome
- Insulin resistance (fasting blood insulin, HOMA-IR)
- Follow-up
- 3 months
Methodological detailssingle-centre, structural equation model analysis
- Single-centre
- Structural equation model analysis
Main finding
As reported in the abstract
Insulin resistance (fasting blood insulin, HOMA-IR), ARNI baseline to 3 months
| Group | Fasting blood insulin, baseline | Homoeostasis model assessment of insulin resistance (HOMA-IR), baseline |
|---|---|---|
| ARNI | 9.7 (7.4, 11.6) μU/mL | 3.10 (1.95, 4.19) |
| Control | 7.8 (5.2, 9.2) μU/mL | 2.02 (1.56, 2.42) |
Fasting blood insulin, baseline
ARNI9.7 (7.4, 11.6) μU/mL
Control7.8 (5.2, 9.2) μU/mL
Homoeostasis model assessment of insulin resistance (HOMA-IR), baseline
ARNI3.10 (1.95, 4.19)
Control2.02 (1.56, 2.42)
- Fasting blood insulin decreased from baseline to 3 months: 9.7 (7.4, 11.6) to 7.3 (4.6, 9.4) μU/mL
- P < 0.001
- HOMA-IR decreased from baseline to 3 months: 3.10 (1.95, 4.19) to 1.96 (1.23, 3.09)
- P < 0.001
- Baseline fasting blood insulin higher in ARNI vs control
- P = 0.033
- Baseline HOMA-IR higher in ARNI vs control
- P = 0.014
Observational data: associations, not effects.
Further findings
| Outcome | ARNI | Control | P value |
|---|---|---|---|
| Baseline insulin resistance | |||
| Fasting insulin | 9.7 (7.4, 11.6) μU/mL | 7.8 (5.2, 9.2) μU/mL | P = 0.033 |
| HOMA-IR | 3.10 (1.95, 4.19) | 2.02 (1.56, 2.42) | P = 0.014 |
| Serum uric acid (ARNI), baseline to 3 months | |||
| Baseline | 6.28 ± 0.35 mg/dL | — not stated in the abstract | |
| Follow-up | 5.80 ± 0.30 mg/dL | — not stated in the abstract | P = 0.008 |
— not stated in the abstract
Original publication
Effects of Angiotensin Receptor-Neprilysin Inhibitor on Insulin Resistance in Patients with Heart Failure. ESC Heart Fail. Published 21 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →